Jenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2025 ,inter alia, to consider and approve standalone unaudited ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals has informed BSE that its Board of Directors will meet on Tuesday, 28 October 2025 at the registered office. The main agenda is to consider and approve the standalone unaudited financial results for the quarter and half year ended 30 September 2025. This is a standard regulatory disclosure under SEBI Listing Regulations. No financial figures have been disclosed yet — they will be known only after the board meeting and subsequent filing. The intimation is signed by Ashish Shah, Sr. Vice President & Company Secretary.
No immediate impact on shareholders or stock price — this is a routine pre-results announcement. Investors should watch for the actual Q2/H1 FY26 numbers once approved and filed.